Pfizer spinout SpringWorks gets FDA priority review for lead drug

A Pfizer spinout is getting a quick date with regulators for its “pipeline-in-a-product.”

SpringWorks Therapeutics announced Monday morning that the FDA granted nirogacestat, the biotech’s lead candidate, priority review for adults with desmoid tumors. Should the drug win approval, it would be the company’s first since being spun out of Pfizer five and a half years ago.